U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07939087) titled 'A Study to Evaluate the Pharmacokinetics and Safety Between HIP2604 and RLD2606 in Healthy Volunteers' on Nov. 10.

Brief Summary: The purpose of this study is to evaluate the pharmacokinetics and safety compared to HIP2604 and RLD2606 in healthy volunteers.

Study Start Date: Jan. 12, 2027

Study Type: INTERVENTIONAL

Condition: Healty Volunteers

Intervention: DRUG: RLD2606

Take 1 tablet once per period

DRUG: HIP2604 1

Take 1 tablet once per period

DRUG: HIP2604 2

Take 1 tablet once per period

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hanmi Pharmaceutical Company Limited

Published by HT Digital Content Services with...